Xilio Therapeutics, Inc. (CIK: 0001840233) EDGAR, Information, Filings... CompaniesBIO.Com

Xilio Therapeutics, Inc.

Mailing address
828 WINTER STREET, WALTHAM, Delaware, 02451
Phone
617-833-1027
State location
Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
SIC
2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS
Filings
N/A

Xilio Therapeutics, Inc. (CIK: 0001840233) is an American company incorporated in the state of Massachusetts. Head office is located at 828 WINTER STREET, WALTHAM, Massachusetts, 02451. Work in the industry 2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS. Xilio Therapeutics, Inc. is a public company and trade via Over-The-Counter (OTC).

Owner	Filings	Transaction Date	Type of Owner
Luptakova Katarina	0001991149	Sep-05-2023	officer: Chief Medical Officer
Frankenfield Christopher James	0001988344	Aug-03-2023	officer: Chief Operating Officer
Brennan Kevin M.	0001971303	Mar-30-2023	officer: SVP, FINANCE AND ACCOUNTING
English Edward C	0001302600	Nov-09-2022	officer: Principal Accounting Officer
Heyman Tomas J.	0001814673	Sep-15-2022	director
ROSS ROBERT W.	0001733077	Jun-15-2022	director
Xu Yuan	0001858214	Jan-04-2022	director
BCIP Life Sciences Associates, LP	0001702921	Oct-26-2021	10 percent owner
Bain Capital Life Sciences Investors, LLC	0001703031	Oct-26-2021	10 percent owner
Bain Capital Life Sciences Fund II, L.P.	0001773187	Oct-26-2021	10 percent owner
Bain Capital Life Sciences Investors II, LLC	0001796155	Oct-26-2021	10 percent owner
BCLS II Investco, LP	0001818893	Oct-26-2021	10 percent owner
BCLS II Investo (GP), LLC	0001819101	Oct-26-2021	10 percent owner
FMR LLC	0000315066	Oct-21-2021	10 percent owner, other: See Remark 1
FIL Ltd	0000318989	Oct-21-2021	10 percent owner, other: See Remark 1
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	0001009258	Oct-21-2021	10 percent owner, other: *Possible Member of 10% Group
Deerfield Mgmt L.P.	0001010823	Oct-21-2021	10 percent owner, other: *Possible Member of 10% Group
LYNCH DANIEL	0001177082	Oct-21-2021	director, 10 percent owner
TOMLINSON SIMON M	0001234289	Oct-21-2021	10 percent owner
CLACKSON TIMOTHY P	0001242992	Oct-21-2021	10 percent owner
Ross Michael Jay	0001254452	Oct-21-2021	director
BAY CITY CAPITAL LLC	0001288452	Oct-21-2021	10 percent owner
DEERFIELD PARTNERS, L.P.	0001301041	Oct-21-2021	10 percent owner, other: *Possible Member of 10% Group
Flynn James E	0001352546	Oct-21-2021	10 percent owner, other: *Possible Member of 10% Group
TAKEDA PHARMACEUTICAL CO LTD	0001395064	Oct-21-2021	10 percent owner
Clancy Paul J	0001409601	Oct-21-2021	director
HUMPHREY RACHEL	0001579781	Oct-21-2021	director
Rock Springs Capital Management LP	0001595725	Oct-21-2021	10 percent owner
Bonstein Sara	0001604019	Oct-21-2021	director
Huber Martin H. Jr.	0001653276	Oct-21-2021	officer: President of R&D and CMO
Atlas Venture Fund XI, L.P.	0001708269	Oct-21-2021	10 percent owner
Alexandria Venture Investments, LLC	0001722024	Oct-21-2021	10 percent owner
Russo Rene	0001722066	Oct-21-2021	director, 10 percent owner, officer: CEO and President
RiverVest Venture Fund IV, L.P.	0001725443	Oct-21-2021	10 percent owner
Rock Springs Capital Master Fund LP	0001735393	Oct-21-2021	10 percent owner
Rock Springs Capital LLC	0001735397	Oct-21-2021	10 percent owner
Rossi Christina	0001756941	Oct-21-2021	director
Atlas Venture Opportunity Fund I, L.P.	0001759241	Oct-21-2021	10 percent owner
Merck KGaA	0001764133	Oct-21-2021	10 percent owner
Takeda Ventures, Inc.	0001771657	Oct-21-2021	10 percent owner
Atlas Venture Associates Opportunity I, L.P.	0001780065	Oct-21-2021	10 percent owner
Atlas Venture Associates Opportunity I, LLC	0001780066	Oct-21-2021	10 percent owner
Atlas Venture Associates XI, LLC	0001780067	Oct-21-2021	10 percent owner
Atlas Venture Associates XI, L.P.	0001780068	Oct-21-2021	10 percent owner
SV7 Impact Medicine Fund LP	0001780602	Oct-21-2021	10 percent owner
Deerfield Mgmt V, L.P.	0001876688	Oct-21-2021	10 percent owner, other: *Possible Member of 10% Group
Curran Daniel J.	0001887599	Oct-21-2021	director
Giovine Salvatore	0001887790	Oct-21-2021	officer: Chief Financial Officer
Four Pines Master Fund LP	0001888685	Oct-21-2021	10 percent owner
Estate of Ulrich Rodeck	0001889447	Oct-21-2021	10 percent owner
SV7 (IMF) GP LLP	0001889859	Oct-21-2021	10 percent owner
Williams John Charles	0001890032	Oct-21-2021	10 percent owner

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Xilio Therapeutics, Inc.

Filings	Format	Description	Filed/Effective	File/Film Number
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001193125-24-258836 (34 Act) Size: KB	Nov-14-2024	005-92962 241464700
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001104659-24-119012 (34 Act) Size: KB	Nov-14-2024	005-92962 241463107
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001172661-24-004587 (34 Act) Size: KB	Nov-12-2024	005-92962 241449378
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0000315066-24-002932 (34 Act) Size: KB	Nov-12-2024	005-92962 241445062
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001558370-24-014775 (34 Act) Size: KB	Nov-07-2024	001-40925 241433523
8-K	Document	Current report filing Acc-no: 0001558370-24-014773 (34 Act) Size: KB	Nov-07-2024	001-40925 241433499
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001415889-24-024463 ( Act) Size: 0 KB	Oct-02-2024
SC 13G	Document	Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001068238-24-000192 (34 Act) Size: KB	Sep-27-2024	005-92962 241336367
3	Document	Initial statement of beneficial ownership of securities Acc-no: 0000950170-24-110147 ( Act) Size: 0 KB	Sep-27-2024
8-K	Document	Current report filing Acc-no: 0001558370-24-012775 (34 Act) Size: KB	Sep-13-2024	001-40925 241297949
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001558370-24-011471 (34 Act) Size: KB	Aug-08-2024	001-40925 241186115
8-K	Document	Current report filing Acc-no: 0001558370-24-011470 (34 Act) Size: KB	Aug-08-2024	001-40925 241186103
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001415889-24-020847 ( Act) Size: 0 KB	Aug-06-2024
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001395064-24-000156 (34 Act) Size: KB	Jul-31-2024	005-92962 241159916
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001415889-24-017210 ( Act) Size: 0 KB	Jun-17-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001415889-24-017208 ( Act) Size: 0 KB	Jun-17-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001415889-24-017207 ( Act) Size: 0 KB	Jun-17-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001415889-24-017206 ( Act) Size: 0 KB	Jun-17-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001415889-24-017205 ( Act) Size: 0 KB	Jun-17-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001415889-24-017204 ( Act) Size: 0 KB	Jun-17-2024

Recent 20 filings. View all Xilio Therapeutics, Inc. filings

Overall rating 5.0

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

Aug 22, 2022

Jean Bishop

Very good communication and delivery made within the timeframe I was advised of

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Xilio Therapeutics, Inc. overview
Xilio Therapeutics, Inc. job
Xilio Therapeutics, Inc. stock
Xilio Therapeutics, Inc. ownership
Xilio Therapeutics, Inc. CEO
Xilio Therapeutics, Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.